Intensity Therapeutics (INTS) vs Kiora Pharmaceuticals (KPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiora Pharmaceuticals (KPRX) has outperformed Intensity Therapeutics (INTS) over the past year, losing 7.3% versus a loss of 48.4%. Intensity Therapeutics is the larger company by market cap ($12.0 million vs $11.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | KPRX |
|---|---|---|
| Share price | $3.68 | $2.53 |
| Market cap | $12.01M | $11.19M |
| 1-day change | -3.16% | 0.00% |
| YTD return | -64.10% | +28.43% |
| 1-year return | -48.35% | -7.33% |
| 5-year return | — | -99.64% |
| EPS (TTM) | $-3.89 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $2.91 |
| 52-week low | $3.21 | $1.77 |
| Distance from 52-week high | -91.54% | -13.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +425.27% | +374.31% |
| Average volume | 25.93K | 17.41K |
| Shares outstanding | 3.26M | 4.42M |
| Employees | 5 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KPRX has outperformed INTS by 41.0 percentage points over the past year.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Healthcare · Biotechnology · 5 employees
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Healthcare · Biotechnology · 13 employees
INTS vs KPRX FAQ
Which is bigger, Intensity Therapeutics or Kiora Pharmaceuticals?
Intensity Therapeutics (INTS) is larger, with a market capitalization of $12.01M compared with $11.19M for Kiora Pharmaceuticals (KPRX).
Which stock has performed better over the past year, INTS or KPRX?
KPRX returned -7.33% over the past 12 months, compared with -48.35% for INTS (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and Kiora Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.